# CytomX Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026
Canonical URL: https://biopharmsignal.com/news/CTMX/cytomx-therapeutics-to-report-first-quarter-2026-financial-results-on-may-7-2026
Ticker: CTMX
Company: CytomX Therapeutics, Inc.
Source: CytomX Therapeutics, Inc.
Published: 2026-04-30 12:00 EST
Original Source URL: https://ir.cytomx.com
## Summary

SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report first quarter financial results on Thursday, May 7, 2026, after the close of U.S.

## Article Body
SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report first quarter financial results on Thursday, May 7, 2026, after the close of U.S.
## Recent Company News
- 2026-06-03 12:00 EST — [CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer](https://biopharmsignal.com/news/CTMX/cytomx-announces-expansion-of-strategic-research-collaboration-with-regeneron-in-the-field-of-conditional-bispecific-therapeutics-for-the-treatment-of-cancer) — Source: CytomX Therapeutics, Inc.
- 2026-05-21 12:00 EST — [CytomX Therapeutics to Present at Upcoming June Investor Conferences](https://biopharmsignal.com/news/CTMX/cytomx-therapeutics-to-present-at-upcoming-june-investor-conferences) — Source: CytomX Therapeutics, Inc.
- 2026-05-18 12:00 EST — [CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs](https://biopharmsignal.com/news/CTMX/cytomx-therapeutics-appoints-mamata-gokhale-ph-d-rac-as-senior-vice-president-of-regulatory-affairs) — Source: CytomX Therapeutics, Inc.
- 2026-05-07 20:15 EST — [CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/CTMX/cytomx-therapeutics-announces-q1-2026-financial-results-and-provides-business-update) — Source: CytomX Therapeutics, Inc.
- 2026-04-30 12:00 EST — [CytomX Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026](https://biopharmsignal.com/news/CTMX/cytomx-therapeutics-to-report-first-quarter-2026-financial-results-on-may-7-2026) — Source: CytomX Therapeutics, Inc.
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)